Unique ID issued by UMIN | UMIN000005678 |
---|---|
Receipt number | R000006716 |
Scientific Title | Clinical trial of hepatic arterial infusion chemotherapy with multidrug resistance-associated protein 3-derived peptide for hepatocellular carcinoma |
Date of disclosure of the study information | 2011/06/01 |
Last modified on | 2012/08/22 12:59:21 |
Clinical trial of hepatic arterial infusion chemotherapy with multidrug resistance-associated protein 3-derived peptide for hepatocellular carcinoma
Hepatic arterial infusion chemotherapy with MRP3-derived peptide for hepatocellular carcinoma
Clinical trial of hepatic arterial infusion chemotherapy with multidrug resistance-associated protein 3-derived peptide for hepatocellular carcinoma
Hepatic arterial infusion chemotherapy with MRP3-derived peptide for hepatocellular carcinoma
Japan |
Hepatocellular carcinoma (HCC)
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate safety and efficacy of MRP3-derived peptide vaccine in hepatic arterial infusion chemotherapy for HCC
Safety,Efficacy
Evaluation of adverse events and immune responses
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Vaccine |
Three times injection of MRP3-derived peptide during hepatic arterial infusion chemotherapy for HCC
20 | years-old | <= |
Not applicable |
Male and Female
1)HCC must be diagnosed and there is an indication of hepatic arterial infusion chemotherapy
2)Karnofsky Performance Status is equal to or more than 70%
3)Patients must be equal to or more than 20 years old and written informed consent must be obtained
4)WBC is equal to or more than 2,000/mm3
5)Platelet is equal to or more than 50,000/mm3
6)Hb is equal to or more than 8.5 g/dl
7)Level of liver damage must be A or B
8)Serum Cr is equal to or less than 1.5 mg/dl
1)Severe complications associated with heart, kidney, lung, blood and coagulability
2)Infection of HIV
3)Past medical history of malignancy
4)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks
5)Past medical history of Immunodeficiency, splenectomy and radiation of spleen
6)medical treatments with steroid
7)Patients who are during lactation
8)Patients who are during pregnancy and expected pregnancy
9)Past history of organ transplantation
10)Patients who are predicted a difficulty of following clinical course
11)Patients who are judged inappropriate for clinical trial
12
1st name | |
Middle name | |
Last name | Shuichi Kaneko |
Kanazawa University Hospital
Department of Gastroenterology
Takara-machi 13-1, Kanazawa city, Ishikawa
1st name | |
Middle name | |
Last name | Eishiro Mizukoshi |
Kanazawa University Hospital
Department of Gastroenterology
076-265-2235
eishirom@m-kanazawa.jp
Department of Gastroenterology, Kanazawa University Hospital
The Ministry of Education, Culture, Sports, Science, and Technology, Japan
Japan
NO
2011 | Year | 06 | Month | 01 | Day |
Unpublished
No longer recruiting
2011 | Year | 02 | Month | 02 | Day |
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 05 | Month | 31 | Day |
2012 | Year | 08 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006716
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |